D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation

Shin Hun Juang, Chia Chi Lung, Pi Chen Hsu, Kuo Shun Hsu, Yu Chen Li, Pao Chiung Hong, Her Shyong Shiah, Ching Chuan Kuo, Ching Wei Huang, Yu Chin Wang, Leeyuan Huang, Tom S. Chen, Shyh Fong Chen, Kuo Chu Fu, Cheng Li Hsu, Meng Ju Lin, Ching Jer Chang, Curtis L. Ashendel, Thomas C K Chan, Kai Ming ChouJang Chang Chang

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

D-501036 [2,5-bis(5-hydroxymethyl-2-selenienyl)-3-hydroxymethyl-N-methylpyrrole] is herein identified as a novel antineoplastic agent with a broad spectrum of antitumoral activity against several human cancer cells and an IC50 value in the nanomolar range. The IC50 values for D-501036 in the renal proximal tubule, normal bronchial epithelial, and fibroblast cells were > 10 μmol/L. D-501036 exhibited no cross-resistance with vincristine- and paclitaxel-resistant cell lines, whereas a low level of resistance toward the etoposide-resistant KB variant was observed. Cell cycle analysis established that D-501036 treatment resulted in a dose-dependent accumulation in S phase with concomitant loss of both the G0-G1 and G2-M phase in both Hep 3B and A-498 cells. Pulsed-field gel electrophoresis showed D-501036-induced, concentration-dependent DNA breaks in both Hep 3B and A-498 cells. These breaks did not involve interference with either topoisomerase-I and topolsomerase-II function or DNA binding. Rapid reactive oxygen species production and formation of Se-DNA adducts were evident following exposure of cells to D-501036, indicating that D-501036 - mediated DNA breaks were attributable to the induction of reactive oxygen species and DNA adduct formation. Moreover, D-501036 - induced DNA damage activated ataxia telangiectasia - mutated nuclear protein kinase, leading to hyperphosphorylation of Chk1, Chk2, and p53, decreased expression of CDC25A, and up-regulation of p2lWAF1 in both p53-proficient and p53-deficient cells. Collectively, the results indicate that D-501036-induced cell death was associated with DNA damage - mediated induction of ataxia telangiectasia - mutated activation, and p53-dependent and -independent apoptosis pathways. Notably, D-501036 shows potent activity against the growth of xenograft tumors of human renal carcinoma A-498 cells. Thus, D-501036 is a promising anticancer compound that has strong potential for the management of human cancers.

Original languageEnglish (US)
Pages (from-to)193-202
Number of pages10
JournalMolecular Cancer Therapeutics
Volume6
Issue number1
DOIs
StatePublished - Jan 2007
Externally publishedYes

Fingerprint

Ataxia Telangiectasia Mutated Proteins
Nuclear Proteins
Protein Kinases
DNA Damage
DNA Breaks
DNA Adducts
Inhibitory Concentration 50
2,5-bis(5-hydroxymethyl-2-selenienyl)-3-hydroxymethyl-N-methylpyrrole
In Vitro Techniques
Reactive Oxygen Species
Ataxia Telangiectasia
Neoplasms
Type I DNA Topoisomerase
Proximal Kidney Tubule
G2 Phase
Pulsed Field Gel Electrophoresis
Vincristine
Etoposide
Paclitaxel
S Phase

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation. / Juang, Shin Hun; Lung, Chia Chi; Hsu, Pi Chen; Hsu, Kuo Shun; Li, Yu Chen; Hong, Pao Chiung; Shiah, Her Shyong; Kuo, Ching Chuan; Huang, Ching Wei; Wang, Yu Chin; Huang, Leeyuan; Chen, Tom S.; Chen, Shyh Fong; Fu, Kuo Chu; Hsu, Cheng Li; Lin, Meng Ju; Chang, Ching Jer; Ashendel, Curtis L.; Chan, Thomas C K; Chou, Kai Ming; Chang, Jang Chang.

In: Molecular Cancer Therapeutics, Vol. 6, No. 1, 01.2007, p. 193-202.

Research output: Contribution to journalArticle

Juang, SH, Lung, CC, Hsu, PC, Hsu, KS, Li, YC, Hong, PC, Shiah, HS, Kuo, CC, Huang, CW, Wang, YC, Huang, L, Chen, TS, Chen, SF, Fu, KC, Hsu, CL, Lin, MJ, Chang, CJ, Ashendel, CL, Chan, TCK, Chou, KM & Chang, JC 2007, 'D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation', Molecular Cancer Therapeutics, vol. 6, no. 1, pp. 193-202. https://doi.org/10.1158/1535-7163.MCT-06-0482
Juang, Shin Hun ; Lung, Chia Chi ; Hsu, Pi Chen ; Hsu, Kuo Shun ; Li, Yu Chen ; Hong, Pao Chiung ; Shiah, Her Shyong ; Kuo, Ching Chuan ; Huang, Ching Wei ; Wang, Yu Chin ; Huang, Leeyuan ; Chen, Tom S. ; Chen, Shyh Fong ; Fu, Kuo Chu ; Hsu, Cheng Li ; Lin, Meng Ju ; Chang, Ching Jer ; Ashendel, Curtis L. ; Chan, Thomas C K ; Chou, Kai Ming ; Chang, Jang Chang. / D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation. In: Molecular Cancer Therapeutics. 2007 ; Vol. 6, No. 1. pp. 193-202.
@article{b1dc61731ff54c7aa4c33de9f954d517,
title = "D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation",
abstract = "D-501036 [2,5-bis(5-hydroxymethyl-2-selenienyl)-3-hydroxymethyl-N-methylpyrrole] is herein identified as a novel antineoplastic agent with a broad spectrum of antitumoral activity against several human cancer cells and an IC50 value in the nanomolar range. The IC50 values for D-501036 in the renal proximal tubule, normal bronchial epithelial, and fibroblast cells were > 10 μmol/L. D-501036 exhibited no cross-resistance with vincristine- and paclitaxel-resistant cell lines, whereas a low level of resistance toward the etoposide-resistant KB variant was observed. Cell cycle analysis established that D-501036 treatment resulted in a dose-dependent accumulation in S phase with concomitant loss of both the G0-G1 and G2-M phase in both Hep 3B and A-498 cells. Pulsed-field gel electrophoresis showed D-501036-induced, concentration-dependent DNA breaks in both Hep 3B and A-498 cells. These breaks did not involve interference with either topoisomerase-I and topolsomerase-II function or DNA binding. Rapid reactive oxygen species production and formation of Se-DNA adducts were evident following exposure of cells to D-501036, indicating that D-501036 - mediated DNA breaks were attributable to the induction of reactive oxygen species and DNA adduct formation. Moreover, D-501036 - induced DNA damage activated ataxia telangiectasia - mutated nuclear protein kinase, leading to hyperphosphorylation of Chk1, Chk2, and p53, decreased expression of CDC25A, and up-regulation of p2lWAF1 in both p53-proficient and p53-deficient cells. Collectively, the results indicate that D-501036-induced cell death was associated with DNA damage - mediated induction of ataxia telangiectasia - mutated activation, and p53-dependent and -independent apoptosis pathways. Notably, D-501036 shows potent activity against the growth of xenograft tumors of human renal carcinoma A-498 cells. Thus, D-501036 is a promising anticancer compound that has strong potential for the management of human cancers.",
author = "Juang, {Shin Hun} and Lung, {Chia Chi} and Hsu, {Pi Chen} and Hsu, {Kuo Shun} and Li, {Yu Chen} and Hong, {Pao Chiung} and Shiah, {Her Shyong} and Kuo, {Ching Chuan} and Huang, {Ching Wei} and Wang, {Yu Chin} and Leeyuan Huang and Chen, {Tom S.} and Chen, {Shyh Fong} and Fu, {Kuo Chu} and Hsu, {Cheng Li} and Lin, {Meng Ju} and Chang, {Ching Jer} and Ashendel, {Curtis L.} and Chan, {Thomas C K} and Chou, {Kai Ming} and Chang, {Jang Chang}",
year = "2007",
month = "1",
doi = "10.1158/1535-7163.MCT-06-0482",
language = "English (US)",
volume = "6",
pages = "193--202",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation

AU - Juang, Shin Hun

AU - Lung, Chia Chi

AU - Hsu, Pi Chen

AU - Hsu, Kuo Shun

AU - Li, Yu Chen

AU - Hong, Pao Chiung

AU - Shiah, Her Shyong

AU - Kuo, Ching Chuan

AU - Huang, Ching Wei

AU - Wang, Yu Chin

AU - Huang, Leeyuan

AU - Chen, Tom S.

AU - Chen, Shyh Fong

AU - Fu, Kuo Chu

AU - Hsu, Cheng Li

AU - Lin, Meng Ju

AU - Chang, Ching Jer

AU - Ashendel, Curtis L.

AU - Chan, Thomas C K

AU - Chou, Kai Ming

AU - Chang, Jang Chang

PY - 2007/1

Y1 - 2007/1

N2 - D-501036 [2,5-bis(5-hydroxymethyl-2-selenienyl)-3-hydroxymethyl-N-methylpyrrole] is herein identified as a novel antineoplastic agent with a broad spectrum of antitumoral activity against several human cancer cells and an IC50 value in the nanomolar range. The IC50 values for D-501036 in the renal proximal tubule, normal bronchial epithelial, and fibroblast cells were > 10 μmol/L. D-501036 exhibited no cross-resistance with vincristine- and paclitaxel-resistant cell lines, whereas a low level of resistance toward the etoposide-resistant KB variant was observed. Cell cycle analysis established that D-501036 treatment resulted in a dose-dependent accumulation in S phase with concomitant loss of both the G0-G1 and G2-M phase in both Hep 3B and A-498 cells. Pulsed-field gel electrophoresis showed D-501036-induced, concentration-dependent DNA breaks in both Hep 3B and A-498 cells. These breaks did not involve interference with either topoisomerase-I and topolsomerase-II function or DNA binding. Rapid reactive oxygen species production and formation of Se-DNA adducts were evident following exposure of cells to D-501036, indicating that D-501036 - mediated DNA breaks were attributable to the induction of reactive oxygen species and DNA adduct formation. Moreover, D-501036 - induced DNA damage activated ataxia telangiectasia - mutated nuclear protein kinase, leading to hyperphosphorylation of Chk1, Chk2, and p53, decreased expression of CDC25A, and up-regulation of p2lWAF1 in both p53-proficient and p53-deficient cells. Collectively, the results indicate that D-501036-induced cell death was associated with DNA damage - mediated induction of ataxia telangiectasia - mutated activation, and p53-dependent and -independent apoptosis pathways. Notably, D-501036 shows potent activity against the growth of xenograft tumors of human renal carcinoma A-498 cells. Thus, D-501036 is a promising anticancer compound that has strong potential for the management of human cancers.

AB - D-501036 [2,5-bis(5-hydroxymethyl-2-selenienyl)-3-hydroxymethyl-N-methylpyrrole] is herein identified as a novel antineoplastic agent with a broad spectrum of antitumoral activity against several human cancer cells and an IC50 value in the nanomolar range. The IC50 values for D-501036 in the renal proximal tubule, normal bronchial epithelial, and fibroblast cells were > 10 μmol/L. D-501036 exhibited no cross-resistance with vincristine- and paclitaxel-resistant cell lines, whereas a low level of resistance toward the etoposide-resistant KB variant was observed. Cell cycle analysis established that D-501036 treatment resulted in a dose-dependent accumulation in S phase with concomitant loss of both the G0-G1 and G2-M phase in both Hep 3B and A-498 cells. Pulsed-field gel electrophoresis showed D-501036-induced, concentration-dependent DNA breaks in both Hep 3B and A-498 cells. These breaks did not involve interference with either topoisomerase-I and topolsomerase-II function or DNA binding. Rapid reactive oxygen species production and formation of Se-DNA adducts were evident following exposure of cells to D-501036, indicating that D-501036 - mediated DNA breaks were attributable to the induction of reactive oxygen species and DNA adduct formation. Moreover, D-501036 - induced DNA damage activated ataxia telangiectasia - mutated nuclear protein kinase, leading to hyperphosphorylation of Chk1, Chk2, and p53, decreased expression of CDC25A, and up-regulation of p2lWAF1 in both p53-proficient and p53-deficient cells. Collectively, the results indicate that D-501036-induced cell death was associated with DNA damage - mediated induction of ataxia telangiectasia - mutated activation, and p53-dependent and -independent apoptosis pathways. Notably, D-501036 shows potent activity against the growth of xenograft tumors of human renal carcinoma A-498 cells. Thus, D-501036 is a promising anticancer compound that has strong potential for the management of human cancers.

UR - http://www.scopus.com/inward/record.url?scp=33846821661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846821661&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-06-0482

DO - 10.1158/1535-7163.MCT-06-0482

M3 - Article

C2 - 17237279

AN - SCOPUS:33846821661

VL - 6

SP - 193

EP - 202

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 1

ER -